Skip to main content
Caplight Logo









Ahammune Biosciences

Ahammune Biosciences

Private
PuneHealthcare & Life Scienceshttps://ahammune.com

Last Round

Series A

Sep 25, 2024

Total Funding Raised

$5M

Company Overview

Ahammune Biosciences is a biotechnology company that develops small molecule-based therapeutics for the treatment of immune-mediated skin diseases, with a primary focus on vitiligo.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug discoveryvitiligo treatmentsmall moleculeclinical trialsdermatologypigmentary disordersbiotechautoimmune skin conditionstherapeutic developmentmelanocyte healthskin diseasedrug pipelinepharma partnering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ahammune Biosciences Comparables

Compare Ahammune Biosciences with similar companies based on industry and business-model similarity.

Ahammune Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Yarrow Bioscience, Inc.
78%
Edesa Biotech Inc
72%
Incyte Corporation
71%

Ahammune Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 25, 2024
Early FundingApr 26, 2021

Key People

Founding team and executive leadership

Parul Ganju

Co-founder And CEO

Founding Team

Ahammune Biosciences Investors

Notable investors and investment history

Ahammune Biosciences investors
InvestorRounds
IAN GroupSeries A, Early Funding
pi VenturesSeries A
Colossa VenturesSeries A
Ideaspring CapitalSeries A, Early Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 20, 2026

    Monthly visitors increased 4390% MoM.

  • Apr 26, 2021

    Led by IAN Group and Ideaspring Capital.

Ahammune Biosciences Filings

Explore SEC and related filing metadata, where available.

Ahammune Biosciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Ahammune Biosciences's valuation, stock price, and market status.

Is Ahammune Biosciences a public or private company?

Ahammune Biosciences is a private company.

What is the current stock price of Ahammune Biosciences?

Ahammune Biosciences is a private company, so its shares have no public market price. Caplight tracks Ahammune Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Ahammune Biosciences worth (valuation)?

Valuation information for Ahammune Biosciences is not publicly available.

Can I buy Ahammune Biosciences stock?

Ahammune Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Ahammune Biosciences's last funding round?

Ahammune Biosciences's most recent funding round was Series A on September 25, 2024.

Who are the main investors in Ahammune Biosciences?

Key investors in Ahammune Biosciences include IAN Group, pi Ventures, Ideaspring Capital.

Will Ahammune Biosciences IPO soon?

No public IPO plans have been announced for Ahammune Biosciences.

How can I track Ahammune Biosciences secondary market activity?

Caplight tracks bids, offers, and trades in Ahammune Biosciences's shares on secondary markets.

Firmographic Details

HeadquartersPune
Employee Range8
Year Founded2016
Last FundingSep 25, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?